A comparison of fluticasone propionate, 100μg twice daily, administered via a CFC and non-CFC propellant, HFA 134a, in adult patients with asthma

Clinical Drug Investigation

Volumn 21, Issue 10, 2001, Pages 695-703

  Stone, D W G ^a   Mairs, M L ^a   Willits, L ^a   Sharma, R K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; FLUTICASONE PROPIONATE; NORFLURANE; PROPELLANT;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

EID: 0034754027     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121100-00004     Document Type: Article

References (27)

1. CFCs and inhalers
2. The continued need for metered-dose inhalers
3. Metered-dose inhalers and CFCs: What respiratory physicians need to know
4. Patient perception of the Diskus inhaler: A comparison with the Turbuhaler inhaler
5. Large doses of total ozone in Antarctica reveal CLO2/NO2 interaction
6. Nimbus 7 satellite measurements of the springtime Antarctic ozone decrease
7. Montreal protocol on substances that deplete the ozone layer
8. GR106642X, a non-chlorinated propellant for use in metered-dose inhalers: Safety, tolerability and pharmacokinetics in healthy volunteers
9. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate
10. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety
11. What is the clinical relevance of in-vitro pharmaceutical data
12. Pharmaceutical transition to non-CFC pressurized metered dose inhalers
13. Dose proportionality of fluticasone propionate from hydrofluorocarbon pressurised metered dose inhalers (pMDI's) and comparability with chlorofluorocarbon pMDI's
14. Clinical efficacy and safety of fluticasone propionate 250 μg twice daily administered via a HFA 134a pressurised metered dose inhaler to patients with mild to moderate asthma
15. Clinical efficacy and safety of fluticasone propionate 1mg per day administered via HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma
16. Assessing equivalence of inhaled drugs
17. Sample size determination for bioequivalence assessment by means of confidence interval
18. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma
19. Comparative efficacy and safety of twice-daily fluticasone propionate powder versus placebo in the treatment of moderate asthma
20. Effectiveness of fluticasone propionate in patients with moderate asthma: A dose ranging study
21. Measures for detecting systemic bioactivity with inhaled and intranasal steroids
22. GR 106642X: A new, non-ozone depleting propellant for inhalers
23. Equivalence of salbutamol 200μg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics
24. Prospective observational cohort safety study to monitor in the introduction of a non-CFC formulation of salbutamol with HFA 134a in the UK
25. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant
26. Efficacy and safety of inhaled corticosteroids
27. The note for guidance on replacement CFC's in metered dose inhalation products